IDELVION PROVIDES THE PROTECTION OF HIGH STEADY-STATE FACTOR IX TROUGH LEVELS

This elevated trough sustaining Factor IX therapy delivered 20% steady-state levels with 7-day dosing

Mean steady-state Factor IX trough levels when dosed every 7 days Mean steady-state Factor IX trough levels when dosed every 7 days

Prolonged bleed protection with high steady-state Factor IX trough levels with 14-day dosing

13% steady-state trough levels with 14-day dosing in patients who are 12 or older than 12 years (mean)1

*Only time points with ≥3 observations are plotted. Steady-state mean trough is calculated from all observations at any time point. The mean dose for patients receiving prophylaxis every 7 days was 37 IU/kg.

EXTENDED HALF‑LIFE. EXTENDED TIME BETWEEN DOSES.

In the pivotal trial, IDELVION delivered a prolonged half‑life

  • In clinical trials, previous Factor IX products used by subjects had an average half-life of 22 hours. Previous Factor IX products refers to plasma-derived Factor IX or rFIX3
  • Half‑life is based on a single dose of 50 IU/kg in adults (≥18 years)
HALF-LIFE 104 HOURS in adults
0 spontaneous bleeds

Achieved in adults and adolescents dosing at 7 or 14 days in pivotal trials

VIEW EFFICACY DATA
MOA molecule - Recombinant IX fusion protein

IDELVION uses albumin fusion technology to extend half‑life with minimal risk of an immune response

SEE THE IDELVION MOA

References: 1. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735. 2. Data on file. Available from CSL Behring as DOF IDL-003. 3. Data on file. Available from CSL Behring as DOF IDL-001.

X
You are now leaving the current website.

Do you want to continue?